Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

WALTHAM, Massachusetts, October 20 /PRNewswire/ --

- The Global Leader in Securitization Broadens Data Set Coupled with Credit Surveillance Expertise

Lewtan Technologies, Inc., the industry's leading source for asset-backed securities surveillance data, analytics, software, and content for the global securitisation industry, today announced the expansion of a recently formed business unit of credit surveillance experts.

MANCHESTER, England, October 21 /PRNewswire/ --

- Solution Selected for Features and Lowest Total Cost of Ownership

Courion(R) Corporation, leaders in access management and compliance, today announced that The Goodyear Tire Rubber Company has selected Courion's Enterprise Provisioning Suite(TM) solution to deliver identity and access management capabilities for users accessing the company's geographically-distributed IT resources. Goodyear selected Courion based on the solution's functionality, manageability and total cost of ownership over time after a rigorous, multi-stage vendor selection process.

KARLSRUHE, Germany, October 20 /PRNewswire/ -- RapidSolution Software AG has just published on its website, at http://audials.com, the 3rd generation of AudialsOne. AudialsOne 3 comprises the new versions of Radiotracker Platinum, Tunebite Platinum, MP3videoraptor Platinum, Audials TV and Tagrunner. With this new version, AudialsOne is leveraging even more the individual products' synergies and thus confidently claims to be the provider of the best software for obtaining and editing media.

The undisputed Number One for the legal creation and expansion of a free music library

PARIS, October 20 /PRNewswire/ --

- With Webwag Mobile 2.0, Internet and Mobile Become One

Webwag, a publisher of Internet and mobile widgets, announced today the launch of Webwag Mobile 2.0, the new version of its mobile widget engine, which will be commercialized in both versions directly to consumers and as a white label.

Webwag Mobile 2.0 aims at the convergence of the Web and the mobile Internet. It has been designed to be practical and easy to use: users need to register only once from their mobile phone or on the Web.

The same content is then offered on both medias.

NERVIANO, Italy, October 21 /PRNewswire/ -- Nerviano Medical Sciences (NMS), the largest pharmaceutical RD facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, today announced a new multi-year agreement with Genentech, Inc.

This new research agreement is the second collaboration agreement signed between Genentech and NMS in less than twelve months.

The two Companies will collaborate in the discovery of antibody drug conjugates for the development of potential anticancer agents.

Genentech, which is a leading oncology company in the United States, will have the exclusive license to fully develop and commercialize licensed products that contain such antibody drug conjugates.

VIENNA, Austria, October 21 /PRNewswire/ --

- Additional Data Presented at United European Gastroenterology Week Show Fistula Healing in Difficult-to-Treat Patients

New data showed that Abbott's HUMIRA(R) (adalimumab) provided long-term treatment of fistulas, with more than half of patients with moderate to severe Crohn's disease experiencing fistula healing at three years, according to clinical research presented today at the United European Gastroenterology Week (UEGW) congress in Vienna. Data also showed response to HUMIRA in difficult-to-treat patients -- those with fistulas who had failed to respond, lost response to, or were intolerant of infliximab.